Community/Retail

Patients with rheumatoid arthritis (RA) who took biologics or triple therapy had a longer fail time than patients who took methotrexate oral monotherapy, suggesting that these treatments may be a good follow-up to failed first-line methotrexate treatment.

Officials with the FDA have extended the approval of vemurafenib (Zelboraf, Genentech) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare blood cancer, making it the first approved treatment for ECD.

In this clip, Kathy Campbell, PharmD, CEO of Medicap Pharmacy, discusses the benefits of interacting with patients about their wellness and offering weight management services in the pharmacy.

Focus on these 5 mental mantras and watch your community pharmacy practice improve like no other.

David DeRemer, PharmD, Assistant Director of Clinical Therapeutics and Incubator, Clinical Associate Professor at the University of Florida College of Pharmacy, discusses resources to help educate patients on oral chemotherapy agents.

Pharmacy Times took to social media this October to celebrate American Pharmacists Month with our annual #ThankAPharmacist campaign. Here are the 10 noteworthy posts from Facebook, Twitter, and Instagram using the hashtag.

Even beyond American Pharmacists Month, pharmacists deserve to be recognized for the important role they play in patient care.

In this clip, Randy Burkholder, Vice President of Policy and Research at PhRMA, discusses the health care policy changes that are needed to help alleviate the financial hardships faced by cancer patients.

Pharmacists have an important role in the care of oncology patients, especially in managing their treatments and providing support to physicians.

The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2017.

At the National Community Oncology Dispensing Association (NCODA) Fall Summit, Mario Lacouture, MD, discussed the importance of managing quality of life conditions, such as skin, hair, and nail conditions, in patients undergoing cancer treatments.

Pharmacists can expect to see considerably more information about the implications of pharmacogenetics for drug treatment in every disease state.

Sixty-seven million at-risk Americans remain unvaccinated for pneumococcal disease

It takes a great deal of time and resources for a manufacturer to complete all the necessary requirements to submit a successful NDA to the FDA for review.

Pharmacists don't have much free time, but it won't take much to make fitness a mainstay with this slick technique.

In June 2017, the European Commission determined that the FDA “has the capability, capacity and procedures in place to carry out GMP inspections at a level equivalent to the EU.”

The application for acalabrutinib in mantle cell lymphoma was previously granted priority review, breakthrough therapy, and orphan drug designations, according to the FDA.

This is the first report on data from the State Unintentional Drug Overdose Reporting System (SUDORS), which tracks fatal opioid overdoses and is a component of CDC’s Enhanced State Opioid Overdose Surveillance (ESOOS) program.

It is never too late to conquer your dreams.